Allele Symbol: Card11m1Btlr Name: mutation 1, Bruce Beutler Chromosome: 5 Alteration at locus: Chemically Induced
Genetic Alterations:
ENU-induced A to
T transversion at position 1791 of the Carma1/Card11 gene, in exon 12.
Genotype Determination:
ES Cell Line: Not Applicable
Strain Description
Phenotype Homozygous phenotype: -No CD8+ T cell
response after immunization and subsequent challenge with antigen-
specific targets.
- No interferon-gamma production by CD8+ T cells after
immunization and stimulation with antigen in vitro.
- No proliferation
or CD25 upregulation after T cell receptor stimulation of T cells.
- No
CD4+Foxp3+ regulatory T cells in thymus, and greatly reduced numbers in
spleen.
- Reduced basal serum immunoglobulin levels.
- Impaired B cell
proliferation.
- No antigen-specific IgG responses after immunization
with ovalbumin.
- Reduced numbers and percentages of natural killer
(NK), NKT, gamma/delta T, memory CD4+ T, and mature B cells.
Heterozygous phenotype:
Mammalian Phenotype Terms:(provided by MGI)Extend all MPTs assigned by genotype
upregulation of CD69 and CD44 by mutant T cells in response to treatment with TCR-crosslinking antibodies is only slightly impaired (nearly normal)
numbers and proportions of macrophages and neutrophils are normal
dendritic cell (DC) numbers and proportions appear normal; cross-priming by DCs is normal, and DCs from mutant mice upregulate costimulatory molecules (CD40, CD80, CD86, MHC class I and II) normally upon stimulation by apoptotic cells or toll-like receptor (TLR) ligands
abnormal CD4-positive, CD25-positive, alpha-beta regulatory T cell morphology (MGI Ref ID J:149767)
regulatory T cells fail to develop when mutant bone marrow is transferred to wild-type mice suggesting defect is intrinsic to hematopoietic pre-cursors
in vitro, less activated CD4+ T cells express the regulatory marker FoxP3
mutant mice fail to kill syngeneic class I MHC-deficient cells (NK cell-specific target cells) injected a week after primary immunization with irradiated ovalbumin (OVA)-expressing cells
in response to treatment with TCR-crosslinking antibodies (alpha-CD3/28), mutant T cells fail to upregulate CD25 (IL-2Ralpha chain), indicating impairment of TCR-mediated T cell activation
in response to treatment with TCR-crosslinking antibodies (alpha-CD3/28), mutant T cells fail to proliferate, indicating impairment of the TCR-mediated T cell proliferation response; the proliferation de fect can be partially rescued by IL-2 treatment of mutant T cells (MGI Ref ID J:139069)
in vitro-expanded CD8+ T cells isolated from mutant mice a week after their immunization with irradiated ovalbumin (OVA) expressing cells fail to undergo secondary expansion upon restimulation (MGI Ref ID J:139069)
while present in reduced numbers, TGF-beta secretion is enhanced in regulatory T cells
decreased interferon-gamma secretion (MGI Ref ID J:139069)
in vitro-expanded CD8+ T cells isolated from mutant mice a week after their immunization with irradiated ovalbumin (OVA) expressing cells fail to produce interferon (IFN) gamma upon restimulation
decreased interleukin-2 secretion (MGI Ref ID J:139069)
mutant T cells do not produce interleukin 2 (IL-2) in response to treatment with TCR-crosslinking antibodies (alpha-CD3/28)
abnormal cytotoxic T cell physiology (MGI Ref ID J:139069)
mutant mice immunized with irradiated ovalbumin (OVA) expressing cells fail to kill OVA (specific antigen) expressing target C57BL/6J splenocytes injected a week later
abnormal double-negative T cell morphology (MGI Ref IDs J:139069, J:149767)
at 4-5 months of age, mutant mice have ~50% incidence of severe dermatitis
hematopoietic system phenotype
abnormal CD4-positive, CD25-positive, alpha-beta regulatory T cell morphology (MGI Ref ID J:149767)
regulatory T cells fail to develop when mutant bone marrow is transferred to wild-type mice suggesting defect is intrinsic to hematopoietic pre-cursors
in vitro, less activated CD4+ T cells express the regulatory marker FoxP3
in response to treatment with TCR-crosslinking antibodies (alpha-CD3/28), mutant T cells fail to upregulate CD25 (IL-2Ralpha chain), indicating impairment of TCR-mediated T cell activation
in response to treatment with TCR-crosslinking antibodies (alpha-CD3/28), mutant T cells fail to proliferate, indicating impairment of the TCR-mediated T cell proliferation response; the proliferation defect can be partially rescued by IL-2 treatment of mutant T cells (MGI Ref ID J:139069)
in vitro-expanded CD8+ T cells isolated from mutant mice a week after their immunization with irradiated ovalbumin (OVA) expressing cells fail to undergo secondary expansion upon restimulation (MGI Ref ID J:139069)
abnormal double-negative T cell morphology (MGI Ref IDs J:139069, J:149767)
Strain Development: The founder homozygous ENU-induced mutant
was backcrossed to C57BL/6J. Heterozygote progeny were mated to the
original mutant and homozygote progeny from this cross have subsequently
been intercrossed to maintain the stock.
Suggested Control Mice:
Wildtype littermates
Research Applications
Cell Biology
Developmental Biology
Diabetes/Obesity
Immunology and Inflammation
Virology
Strain Origin
Donor:
Bruce Beutler, M.D., The Scripps Research Institute
Primary Reference:
Barnes MJ; Krebs P; Harris N; Eidenschenk C; Gonzalez-Quintial R; Arnold CN; Crozat K; Sovath S; Moresco EM; Theofilopoulos AN; Beutler B; Hoebe K, Commitment to the regulatory T cell lineage requires CARMA1 in the thymus but not in the periphery., PLoS Biol 2009 Mar 3;7(3):e51
(Medline PMID: 19260764)
For additional information see: Mutagenetix, a catalog of mutations identified in the Beutler Laboratory at The Scripps Research Institute.
Special Considerations
Donor notes homozygotes are susceptible to infection and dermatitis.
Health Status Report
Mice recovered from a cryo-archive will have health surveillance performed on recipient females. Health reports will be provided prior to shipment. If you require additional health status information, please email mmrrc@ucdavis.edu.
Order Request Information
Availability Level:
Limited quantities of breeder mice (recovered litter) are available from a cryoarchive; recovered litter usually available to ship in 3 to 4 months.
Conditions of Distribution:
Distribution of this strain requires submission of the MMRRC Conditions of Use (COU).
A link to the COU web form will be provided via email after an order has been placed; the form should be completed then or the email forwarded
to your institutional official for completion.
The donor or their institution limits the distribution to non-profit institutions only.
Fees:
Additional charges may apply for any special requests. Shipping
costs are in addition to the basic distribution/resuscitation
fees. Information on shipping costs and any additional charges will be provided
by the supplying MMRRC facility.
Click button to Request this one strain.
(Use the MMRRC Catalog Search to request more than one strain.)
MMRRC Item #
Description
Distribution
Fee/unit (US $)
Units
Notes
030114-UCD-RESUS
Litter recovered from cryo-archive
$2,022.00
Non-Profit
Litter
Recovered litter1; additional fees for any special requests.
030114-UCD-SPERM
Cryo-preserved spermatozoa
$437.00
Non-Profit
Aliquot
Approximate quantity.2
030114-UCD-EMBRYO
Cryo-preserved embryos
$1,038.00
Non-Profit
Aliquot
Approximate quantity3: 20-40 embryos / aliquot
1
The distribution fee covers the expense of resuscitating mice from the cryo-archive; you will receive the resulting litter. The litter will contain at minimum one mutant carrier; the actual number of animals and the gender and genotype ratios will vary. (Typically, multiple breeder pairs can be established from the recovered litter.) Prior to shipment, the MMRRC will provide information about the animals recovered. If you anticipate or find that you need to request specific genotypes, genders or quantities of mice in excess of what is likely from a resuscitated litter, you may discuss available options and pricing with the supplying MMRRC facility.
2
An aliquot is one straw or vial with sufficient sperm to recover at least one litter of mice, as per provided protocols, when performed at the MMRRC facility. The MMRRC makes no guarantee concerning the success of these procedures when performed outside the MMRRC facilities.
3
An aliquot contains a sufficient number of embryos (in one or more
vials and based on the transfer success rate of the MMRRC facility) to
transfer to at least two recipients. The MMRRC makes no guarantee concerning
embryo transfer success experienced in the recipient investigator's laboratory.
Neither gender nor genotype ratios are guaranteed.
To request material from the MMRRC: Please fill out our on-line request form (accessible from the catalog search results page, or click the "Request this Strain" button above). If you have questions or need assistance completing this form, you may call Customer Service at (800) 910-2291 (in USA or Canada) or (530) 757-5710 (international calls). Before you call, please have with you: the MMRRC item number, quantity needed, Bill-to and Ship-to contact information.
The MMRRC is a collaborative effort, funded by grants from the
NIH
This site requires JavaScript. Tested for Firefox 3.5+, Microsoft Internet Explorer 7+,
Google Chrome.